Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments

Shin Jie Yong, Shin Jie Yong

Abstract

Long COVID or post-COVID-19 syndrome first gained widespread recognition among social support groups and later in scientific and medical communities. This illness is poorly understood as it affects COVID-19 survivors at all levels of disease severity, even younger adults, children, and those not hospitalized. While the precise definition of long COVID may be lacking, the most common symptoms reported in many studies are fatigue and dyspnoea that last for months after acute COVID-19. Other persistent symptoms may include cognitive and mental impairments, chest and joint pains, palpitations, myalgia, smell and taste dysfunctions, cough, headache, and gastrointestinal and cardiac issues. Presently, there is limited literature discussing the possible pathophysiology, risk factors, and treatments in long COVID, which the current review aims to address. In brief, long COVID may be driven by long-term tissue damage (e.g. lung, brain, and heart) and pathological inflammation (e.g. from viral persistence, immune dysregulation, and autoimmunity). The associated risk factors may include female sex, more than five early symptoms, early dyspnoea, prior psychiatric disorders, and specific biomarkers (e.g. D-dimer, CRP, and lymphocyte count), although more research is required to substantiate such risk factors. While preliminary evidence suggests that personalized rehabilitation training may help certain long COVID cases, therapeutic drugs repurposed from other similar conditions, such as myalgic encephalomyelitis or chronic fatigue syndrome, postural orthostatic tachycardia syndrome, and mast cell activation syndrome, also hold potential. In sum, this review hopes to provide the current understanding of what is known about long COVID.

Keywords: Long-haul COVID-19; drug repurposing; long COVID; pathophysiology; post-COVID-19 syndrome; risk factors.

Conflict of interest statement

The author states that there is no conflict of interest to disclose.

Figures

Figure 1.
Figure 1.
An overview of the symptoms, putative pathophysiology, associated risk factors, and potential treatments involved in long COVID. Note: Dashed lines represent areas where evidence is relatively lacking compared to non-dashed lines. (Color online only).

References

    1. Hu B, Guo H, Zhou P, et al. . Characteristics of SARS-CoV-2 and COVID. Nat Rev Microbiol. 2020;19(3):141–154.
    1. Maxwell E. 'Living with Covid19: A dynamic review of the evidence around ongoing Covid19 symptoms (often called Long Covid).', (updated 30th September 2020) <>, accessed 31st January 2021.
    1. Rubin R. As Their Numbers Grow, COVID-19 “Long Haulers” Stump Experts. JAMA. 2020;324(14):1381–1383.
    1. Callard F, Perego E.. How and why patients made Long Covid. Social Science & Medicine. 2021;268:113426.
    1. Altmann DM, Boyton RJ.. Decoding the unknowns in long covid. BMJ. 2021;372:n132.
    1. Baig AM. Deleterious outcomes in long-Hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem Neurosci. 2020;11(24);4017–4020.
    1. Venkatesan P. NICE guideline on long COVID'. The Lancet Respiratory Medicine. 2021;9(2):129.
    1. Nath A. Long-Haul COVID. Neurology. 2020;95(13):559–560.
    1. Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27(1):28–33.
    1. Davido B, et al. . Post-COVID-19 chronic symptoms: a postinfectious entity? Clin Microbiol Infect. 2020;26(11):1448–1449.
    1. Datta SD, Talwar A, Lee JT.. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251–2252.
    1. Mendelson M, Nel J, Blumberg L, et al. . Long-COVID: An evolving problem with an extensive impact. S Afr Med J. 2020;111(1):10–12.
    1. Sivan M, Taylor S.. NICE guideline on long covid. BMJ. 2020;371:m4938.
    1. Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615.
    1. Fernandez-de-Las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, et al. . Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification'. Int J Environ Res Public Health. 2021;18(5):2621.
    1. Greenhalgh T, Knight M, A’Court C, et al. . Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.
    1. Shah W, Hillman T, Playford ED, et al. . Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136.
    1. Cares-Marambio K, Montenegro-Jiménez Y, Torres-Castro R, et al. . Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Chron Respir Dis. 2021;18:14799731211002240.
    1. Arnold DT, Hamilton FW, Milne A, et al. . Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2020;76:399–401.
    1. Bellan M, Soddu D, Balbo PE, et al. . Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw Open. 2021;4(1):e2036142.
    1. Carfi A, et al. . Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–605.
    1. Cirulli ET, Schiabor Barrett KM, Riffle S, et al. . Long-term COVID-19 symptoms in a large unselected population. medRxiv. 2020. DOI:10.1101/2020.10.07.20208702
    1. Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an International Cohort: 7 months of symptoms and their impact. medRxiv. 2020. DOI:10.1101/2020.12.24.20248802
    1. Dennis A, Wamil M, Alberts J, et al. . Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11(3):e048391.
    1. Garrigues E, Janvier P ,Kherabi Y, et al. . Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4–e6.
    1. Han X, Fan Y, Alwalid O, et al. . Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology. 2021;299(1):E177–E186.
    1. Huang C, Huang L, Wang Y, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2021;397(10270):220–232.
    1. Lerum TV, Aaløkken TM, Brønstad E, et al. . Dyspnoea, lung function and CT findings three months after hospital admission for COVID. Eur Respir J. 2021;57(4):2003448.
    1. Liang L, Yang B, Jiang N, et al. . Three-month Follow-up Study of Survivors of Coronavirus Disease 2019 after Discharge. J Korean Med Sci. 2020;35(47):e418.
    1. Lu Y, Li X, Geng D, et al. . Cerebral micro-structural changes in COVID-19 patients – An MRI-based 3-month follow-up study. EClinicalMedicine. 2020;25:100484.
    1. Miyazato Y, Morioka S, Tsuzuki S, et al. . Prolonged and late-onset symptoms of coronavirus disease 2019. Open Forum Infect Dis. 2020;7(11):ofaa507.
    1. Petersen MS, Kristiansen MF, Hanusson KD, et al. . Long COVID in the Faroe Islands – a longitudinal study among non-hospitalized patients. Clin Infect Dis. 2020;ciaa1792.
    1. Simani L, Ramezani M, Darazam IA, et al. . Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. J Neurovirol. 2021;27(1):154–159.
    1. Shah AS, Wong AW, Hague CJ, et al. . A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021;76(4):402–404.
    1. Sonnweber T, Sahanic S, Pizzini A, et al. . Cardiopulmonary recovery after COVID-19 – an observational prospective multi-center trial'. ' Eur Respir J. 2020;57(4):2003481.
    1. Stavem K, Ghanima W, Olsen MK, et al. . 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax. 2021;76(4):405.
    1. Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of long COVID. Nat Med. 2021;27(4):626–631.
    1. Taboada M, Carinena A, Moreno E, et al. . Post-COVID-19 functional status six-months after hospitalization. J Infect. 2020;82(4):e31–e33.
    1. Townsend L, Dyer AH, Jones K, et al. . Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784.
    1. Truffaut L, Demey L, Bruyneel AV, et al. . Post-discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission. Respir Res. 2021;22(1):29.
    1. van den Borst B, et al. . Comprehensive health assessment three months after recovery from acute COVID-19. Clin Infect Dis. 2020;ciaa1750.
    1. van Gassel RJJ, Bels JLM, Raafs A, et al. . High Prevalence of Pulmonary Sequelae at 3 Months After Hospital Discharge in Mechanically Ventilated COVID-19 Survivors. Am J Respir Crit Care Med. 2021;203(3):371–374.
    1. Wong AW, Shah AS, Johnston JC, et al. . Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J. 2020;56(5):2003276.
    1. Woo MS, Malsy J, Pottgen J, et al. . Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun. 2020;2(2):fcaa205.
    1. Xiong Q, Xu M, Li J, et al. . Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study'. Clin Microbiol Infect. 2021;27(1):89–95.
    1. Zhao YM, Shang YM, Song WB, et al. . Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463.
    1. McMahon DE, Gallman AE, Hruza GJ, et al. . Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. The Lancet Infectious Diseases. 2021;21(3):313–314.
    1. Amenta EM, et al. . Postacute COVID-19: An Overview and Approach to Classification. Open Forum Infect Dis. 2020;7(12):ofaa509.
    1. Rando HM, Bennett TD, Byrd JB, et al. . Challenges in defining Long COVID: Striking differences across literature, Electronic Health Records, and patient-reported information. medRxiv. 2021. DOI:10.1101/2021.03.20.21253896
    1. Townsend L, Dowds J, O'Brien K, et al. . Persistent poor health post-COVID-19 is not associated with respiratory complications or initial disease severity. Ann Am Thorac Soc. 2021. DOI:10.1513/AnnalsATS.202009-1175OC
    1. Buonsenso D, Espuny Pujol F, Munblit D, et al. . Clinical characteristics, activity levels and mental health problems in children with Long COVID: a survey of 510 children. Preprints. 2021. DOI:10.20944/preprints202103.0271.v1
    1. Buonsenso D, Munblit D, De Rose C, et al. . Preliminary Evidence on Long Covid in children. Acta Paediatr. 2021. DOI:10.1111/apa.15870
    1. Ludvigsson JF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID. Acta Paediatr. 2021;110(3):914–921.
    1. Das KM, Lee EY, Singh R, et al. . Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging. 2017;27(3):342–349.
    1. Lee SH, Shin H-S, Park HY, et al. . Depression as a Mediator of Chronic Fatigue and Post-Traumatic Stress Symptoms in Middle East Respiratory Syndrome Survivors. Psychiatry Investig. 2019;16(1):59–64.
    1. Lam MH. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med. 2009;169(22):2142–2147.
    1. Ngai JC, Ko FW, Ng SS, et al. . The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology. 2010;15(3):543–550.
    1. Rogers JP, Chesney E, Oliver D, et al. . Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. The Lancet Psychiatry. 2020;7(7):611–627.
    1. Zhang P, Li J, Liu H, et al. . Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. 2020;8(1):8.
    1. Zhao FC, Guo KJ, Li ZR.. Osteonecrosis of the femoral head in SARS patients: seven years later. Eur J Orthop Surg Traumatol. 2013;23(6):671–677.
    1. Liu D, Zhang W, Pan F, et al. . The pulmonary sequalae in discharged patients with COVID-19: a short-term observational study. Respir Res. 2020;21(1):125.
    1. Marvisi M, Ferrozzi F, Balzarini L, et al. . First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution. Int J Infect Dis. 2020;99:485–488.
    1. Wei J, Yang H, Lei P, et al. . Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge. J Xray Sci Technol. 2020;28(3):383–389.
    1. Li H, Zhao X, Wang Y, et al. . Damaged lung gas-exchange function of discharged COVID-19 patients detected by hyperpolarized (129)Xe MRI. Sci Adv. 2020;7(1):eabc8180.
    1. Crameri GAG, Bielecki M, Züst R, et al. . Reduced maximal aerobic capacity after COVID-19 in young adult recruits, Switzerland, May 2020. Euro Surveill. 2020;25(36):2001542.
    1. Krishna R, Chapman K, Ullah S.. 2020. 'Idiopathic Pulmonary Fibrosis', StatPearls (Treasure Island (FL)).
    1. Swigris JJ, Streiner DL, Brown KK, et al. . Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(1):181–188.
    1. Paterson RW, Brown RL, Benjamin L, et al. . The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020;143(10):3104–3120.
    1. Mao L, Jin H, Wang M, et al. . Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690.
    1. Mendez R, Balanzá-Martínez V, Luperdi SC, et al. . Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. J Intern Med. 2021. DOI:10.1111/joim.13262
    1. O'Hanlon S, Inouye SK.. Delirium: a missing piece in the COVID-19 pandemic puzzle. Age Ageing. 2020;49(4):497–498.
    1. Girard TD, Jackson JC, Pandharipande PP, et al. . Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. Crit Care Med. 2010;38(7):1513–1520.
    1. Gross AL, Jones RN, Habtemariam DA, et al. . Delirium and long-term cognitive trajectory among persons with dementia. Arch Intern Med. 2012;172(17):1324–1331.
    1. Dani M, Dirksen A, Taraborrelli P, et al. . Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med. 2021;21(1):e63–e67.
    1. Taquet M, Geddes JR, Husain M, et al. . 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records'. The Lancet Psychiatry. 2021;8(5):416–427.
    1. Ackermann M, Verleden SE, Kuehnel M, et al. . Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120–128.
    1. Chu H, Chan JF, Yuen TT, et al. . Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. The Lancet Microbe. 2020;1(1):e14–e23.
    1. Sun S-H, Chen Q, Gu H-J, et al. . A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. Cell Host Microbe. 2020;28(1):124–133 e4.
    1. von Weyhern CH, Kaufmann I, Neff F, et al. . Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. The Lancet. 2020;395(10241):e109.
    1. Zhang B-Z, Chu H, Han S, et al. . SARS-CoV-2 infects human neural progenitor cells and brain organoids. Cell Res. 2020;30(10):928–931.
    1. Gandhi S, Srivastava AK, Ray U, et al. . Is the collapse of the respiratory center in the brain responsible for respiratory breakdown in COVID-19 patients? ACS Chem Neurosci. 2020;11(10):1379–1381.
    1. Li YC, Bai WZ, Hashikawa T.. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552–555.
    1. Yong SJ. Persistent Brainstem Dysfunction in Long-COVID: A Hypothesis. ACS Chem Neurosci. 2021;12(4):573–580.
    1. Lukiw WJ, Pogue A, Hill JM.. SARS-CoV-2 Infectivity and Neurological Targets in the Brain. Cell Mol Neurobiol. 2020. DOI:10.1007/s10571-020-00947-7
    1. Matschke J, Lütgehetmann M, Hagel C, et al. . Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. The Lancet Neurology. 2020;19(11):919–929.
    1. Meinhardt J, Radke J, Dittmeyer C, et al. . Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2020;24:168–175.
    1. Solomon IH, Normandin E, Bhattacharyya S, et al. . Neuropathological Features of Covid-19. N Engl J Med. 2020;383(10):989–992.
    1. Puntmann VO, Carerj ML, Wieters I, et al. . Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265–1273.
    1. Rajpal S, Tong MS, Borchers J, et al. . Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 2020;6(1):116–118.
    1. Moody WE, Liu B, Mahmoud-Elsayed HM, et al. . Persisting Adverse Ventricular Remodeling in COVID-19 Survivors: A Longitudinal Echocardiographic Study. Journal of the American Society of Echocardiography. 2021;34(5):562–566.
    1. Del Rio C, Collins LF, Malani P.. Long-term Health Consequences of COVID. JAMA. 2020;324(17):1723. ),
    1. Mitrani RD, Dabas N, Goldberger JJ.. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. Heart Rhythm. 2020;17(11):1984–1990.
    1. Raman B, Cassar MP, Tunnicliffe EM, et al. . Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine. 2021;31:100683.
    1. Ayoubkhani D, Khunti K, Nafilyan V, et al. . Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693.
    1. Carmo A, Pereira‐Vaz J, Mota V, et al. . Clearance and persistence of SARS-CoV-2 RNA in patients with COVID. J Med Virol. 2020;92(10):2227–2231.
    1. Kandetu TB, Dziuban EJ, Sikuvi K, et al. . Persistence of positive RT-PCR results for over 70 days in two travelers with COVID-19. Disaster Med Public Health Prep. 2020. DOI:10.1017/dmp.2020.450
    1. Vibholm LK, Nielsen SSF, Pahus MH, et al. . SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine. 2021;64:103230.
    1. Wang X, Huang K, Jiang H, et al. . Long-term existence of SARS-CoV-2 in COVID-19 patients: host immunity, viral virulence, and transmissibility. Virol Sin. 2020;35(6):793–802.
    1. Hirotsu Y, Maejima M, Shibusawa M, et al. . Analysis of a persistent viral shedding patient infected with SARS-CoV-2 by RT-qPCR, FilmArray Respiratory Panel v2.1, and antigen detection. J Infect Chemother. 2020;27(2):406–409.
    1. Li Q, Zheng XS, Shen XR, et al. . Prolonged shedding of severe acute respiratory syndrome coronavirus 2 in patients with COVID-19. Emerg Microbes Infect. 2020;9(1):1–28.
    1. Park SK, Lee C, Park D, et al. . Detection of SARS-CoV-2 in fecal samples from patients with asymptomatic and mild COVID-19 in Korea. Clin Gastroenterol Hepatol. 2020. DOI:10.1016/j.cgh.2020.06.005
    1. Wu Y, Guo C, Tang L, et al. . Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. 2020;5(5):434–435.
    1. Gaebler C, Wang Z, Lorenz JCC, et al. . Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639–644.
    1. Karlsson AC, Humbert M, Buggert M.. The known unknowns of T cell immunity to COVID. Sci Immunol. 2020;5(53):19.
    1. Ehrenfeld M, Tincani A, Andreoli L, et al. . Covid-19 and autoimmunity. Autoimmun Rev. 2020;19(8):102597.
    1. Lui DTW, Lee CH, Chow WS, et al. . Thyroid dysfunction in relation to immune profile, disease status and outcome in 191 patients with COVID-19. J Clin Endocrinol Metab. 2020;106(2):e926–e935.
    1. Muller I, Cannavaro D, Dazzi D, et al. . SARS-CoV-2-related atypical thyroiditis. The Lancet Diabetes & Endocrinology. 2020;8(9):739–741.
    1. Li Q, Wang B, Mu K, et al. . The pathogenesis of thyroid autoimmune diseases: New T lymphocytes – Cytokines circuits beyond the Th1-Th2 paradigm. J Cell Physiol. 2019;234(3):2204–2216.
    1. Zuo Y, Estes SK, Ali RA, et al. . Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12:eabd3876.
    1. Bastard P, Rosen LB, Zhang Q, et al. . Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;(6515):370.
    1. Gao ZW, Zhang H, Liu C, et al. . Autoantibodies in COVID-19: frequency and function. Autoimmun Rev. 2021;20(3):102754.
    1. Vlachoyiannopoulos PG, Magira E, Alexopoulos H, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020;79(12):1661–1663.
    1. Zhou Y, Han T, Chen J, et al. . Clinical and autoimmune characteristics of severe and critical cases of COVID. Clin Transl Sci. 2020;13(6):1077–1086.
    1. Elkon K, Casali P.. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol. 2008;4(9):491–498.
    1. Cojocaru M, Cojocaru IM, Silosi I, et al. . Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011;6(4):330–336.
    1. Guo Q, Wang Y, Xu D, et al. . Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15.
    1. Fathi N, Rezaei N.. Lymphopenia in COVID-19: therapeutic opportunities. Cell Biol Int. 2020;44(9):1792–1797.
    1. Tavakolpour S, Rakhshandehroo T, Wei EX, et al. . Lymphopenia during the COVID-19 infection: What it shows and what can be learned. Immunol Lett. 2020;225:31–32.
    1. Cheng Y, Zhao H, Song P, et al. . Dynamic changes of lymphocyte counts in adult patients with severe pandemic H1N1 influenza A. J Infect Public Health. 2019;12(6):878–883.
    1. Kong M, Zhang H, Cao X, et al. . Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. Epidemiol Infect. 2020;148:e139.
    1. Danwang C, Endomba FT, Nkeck JR, et al. . A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020;8(1):37.
    1. Malik P, Patel U, Mehta D, et al. . Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2020. DOI:10.1136/bmjebm-2020-111536
    1. Ou M, Zhu J, Ji P, et al. . Risk factors of severe cases with COVID-19: a meta-analysis. Epidemiol Infect. 2020;148:e175.
    1. Hu F, Chen F, Ou Z, et al. . A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract. Cell Mol Immunol. 2020;17(11):1119–1125.
    1. Liu B, Han J, Cheng X, et al. . Reduced numbers of T cells and B cells correlates with persistent SARS-CoV-2 presence in non-severe COVID-19 patients. Sci Rep. 2020;10(1):17718.
    1. Amato MK, Hennessy C, Shah K, et al. . Multisystem inflammatory syndrome in an adult. J Emerg Med. 2021. DOI:10.1016/j.jemermed.2021.02.007
    1. Belot A, Antona D, Renolleau S, et al. . SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. Euro Surveill. 2020;25(22):2001010.
    1. Morris SB, Schwartz NG, Patel P, et al. . Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection – United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(40):1450–1456.
    1. Toubiana J, Poirault C, Corsia A, et al. . Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020;369:m2094.
    1. Whittaker E, Bamford A, Kenny J, et al. . Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020;324(3):259–269.
    1. Roe K. A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms. Inflammopharmacol. 2020;28(5):1219–1222.
    1. Sollini M, et al. . Vasculitis changes in COVID-19 survivors with persistent symptoms: an [(18)F]FDG-PET/CT study'. Eur J Nucl Med Mol Imaging. 2020;48(5):1460–1466.
    1. Zhou M, Yin Z, Xu J, et al. . Inflammatory profiles and clinical features of COVID-19 survivors three months after discharge in Wuhan, China. J Infect Dis. 2021;jiab181. DOI:10.1093/infdis/jiab181
    1. Kucuk A, Cumhur Cure M, Cure E.. Can COVID-19 cause myalgia with a completely different mechanism? A hypothesis. Clin Rheumatol. 2020;39(7):2103–2104.
    1. Lacourt TE, Vichaya EG, Chiu GS, et al. . The high costs of low-grade inflammation: persistent fatigue as a consequence of reduced cellular-energy availability and non-adaptive energy expenditure. Front Behav Neurosci. 2018;12:78.
    1. Komaroff AL, Bateman L.. Will COVID-19 Lead to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? Front Med. 2021;7: 1132.
    1. Maksoud R, Preez S, Eaton-Fitch N, et al. A systematic review of neurological impairments in myalgic encephalomyelitis/ chronic fatigue syndrome using neuroimaging techniques. PLoS One. 2020;15(4):e0232475.
    1. Lamers MM, Beumer J, Vaart J, et al. . SARS-CoV-2 productively infects human gut enterocytes. Science. 2020;369(6499):50–54.
    1. Xiao F, Tang M, Zheng X, et al. . Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831–1833 e3.
    1. Zang R, Castro MFG, McCune BT, et al. . TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. 2020;5(47):eabc3582.
    1. Cheung KS, Hung IFN, Chan PPY, et al. . Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong Cohort: systematic review and meta-analysis. Gastroenterology. 2020;159(1):81–95.
    1. Mao R, Qiu Y, He JS, et al. . Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667–678.
    1. Yeoh YK, Zuo T, Lui GC-Y, et al. . Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70(4):698–706.
    1. Zuo T, Zhan H, Zhang F, et al. . Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge. Gastroenterology. 2020;159(4):1302–1310 e5.
    1. Zuo T, Zhang F, Lui GCY, et al. . Alterations in gut microbiota of patients with covid-19 during time of hospitalization. Gastroenterology. 2020;159(3):944–955 e8.
    1. Belkaid Y, Hand TW.. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121–141.
    1. Yong SJ, Tong T, Chew J, et al. . Antidepressive mechanisms of probiotics and their therapeutic potential. Front Neurosci. 2019;13:1361.
    1. Liao B, Liu Z, Tang L, et al. . Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19. Int J Med Sci. 2021;18(1):29–41.
    1. Mandal S, Barnett J, Brill SE, et al. . Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID. Thorax. 2021;76(4):396–398.
    1. Moreno-Pérez O, Merino E, Leon-Ramirez J-M, et al. . Post-acute COVID-19 Syndrome. Incidence and risk factors: a Mediterranean cohort study. Journal of Infection. 2021;82(3):378–383.
    1. Salmon D, Slama D, Broucker TD, et al. . Clinical, virological and imaging profile in patients with Persistent or Resurgent forms of COVID-19: a cross-sectional study. J Infect. 2020;82(2): e1–e4.
    1. Katsanos AH, Kyriakidi K, Karassa FB, et al. . Biomarker development in chronic inflammatory diseases'. Biomarkers for Endometriosis. 2017;41–75.
    1. Tektonidou MG, Ward MM.. Validation of new biomarkers in systemic autoimmune diseases. Nat Rev Rheumatol. 2011;7(12):708–717.
    1. Poyraz BC, Poyraz CA, Qlgun Y, et al. . Psychiatric morbidity and protracted symptoms after COVID-19. Psychiatry Res. 2020;295:113604.
    1. Halpin SJ, Mclvor C, Whyatt G, et al. . Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021;93(2):1013–1022.
    1. Sigfrid L, Drake TM, Pauley E, et al. . Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. medRxiv. 2021. DOI:10.1101
    2. /2021.0
    3. 3.18.21253888
    1. Valent A, Dudoignon E, Ressaire Q, et al. . Three-month quality of life in survivors of ARDS due to COVID-19: A preliminary report from a French academic centre. Anaesth Crit Care Pain Med. 2020;39(6):740–741.
    1. Inoue S, Hatakeyama J, Kondo Y, et al. . Post-intensive care syndrome: its pathophysiology, prevention, and future directions. Acute Med Surg. 2019;6(3):233–246.
    1. Rawal G, Yadav S, Kumar R.. Post-intensive Care Syndrome: an Overview. J Transl Int Med. 2017;5(2):90–92.
    1. Greenhalgh T, Knight M.. Long COVID: a primer for family physicians. Am Fam Physician. 2020;102(12):716–717.
    1. Wang TJ, Chau B, Lui M, et al. . Physical Medicine and Rehabilitation and Pulmonary Rehabilitation for COVID-19. Am J Phys Med Rehabil. 2020;99(9):769–774.
    1. Barker-Davies RM, Sullivan OO, Senaratne KPP, et al. . The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med. 2020;54(16):949–959.
    1. Sivan M, Rayner C, Delaney B.. Fresh evidence of the scale and scope of long covid'. BMJ. 2021;373:n853.
    1. Puchner B, Sahanic S, Kirchmair R, et al. . Beneficial effects of multi-disciplinary rehabilitation in post-acute COVID-19 – an observational cohort study. Eur J Phys Rehabil Med. 2021;57(2):189–198.
    1. Ferraro F, Calafiore D, Dambruoso F, et al. . COVID-19 related fatigue: which role for rehabilitation in post-COVID-19 patients? A case series. J Med Virol. 2021;93(4):1896–1899.
    1. Liu K, Zhang W, Yang Y, et al. Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study. Complement Ther Clin Pract. 2020;39:101166.
    1. Demeco A, Marotta N, Barletta M, et al. . Rehabilitation of patients post-COVID-19 infection: a literature review. J Int Med Res. 2020;48(8):300060520948382.
    1. Jadhav K, Jariwala P.. ‘Ivabradin’ versus ‘Carvedilol’ in the management of Post-COVID-19 palpitation with sinus tachycardia. Indian Heart Journal. 2020;72:S33.
    1. Fukuda K, Straus SE, Hickie I, et al. . The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121(12):953–959.
    1. Kim DY, Lee JS, Park SY, et al. . Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Transl Med. 2020;18(1):7.
    1. Richman S, Morris MC, Bordrick G, et al. . Pharmaceutical interventions in chronic fatigue syndrome: a literature-based commentary. Clin Ther. 2019;41(5):798–805.
    1. Sapra A, Bhandari P.. 2020. 'Chronic Fatigue Syndrome', StatPearls (Treasure Island (FL)).
    1. Strayer DR, Young D, Mitchell WM.. Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. PLoS One. 2020;15(10):e0240403.
    1. Blitshteyn S, Whitelaw S.. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol Res. 2021;69(2):212–212.
    1. Bryarly M, Philips LT, Fu Q, et al. . Postural orthostatic tachycardia syndrome: JACC focus seminar. J Am Coll Cardiol. 2019;73(10):1207–1228.
    1. Akin C, Valent P, Metcalfe DD.. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6):1099–1104 e4.
    1. Molderings GJ, Brettner S, Homann J, et al. . Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011;4(1):10.
    1. Fu Q, Levine BD.. Exercise and non-pharmacological treatment of POTS. Auton Neurosci. 2018;215:20–27.
    1. Larun L, Brurberg KG, Odgaard-Jensen J, et al. . Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev. 2019;10:CD003200.
    1. Twisk FN, Maes M.. A review on cognitive behavorial therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME) / chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. Neuro Endocrinol Lett. 2009;30(3):284–299.
    1. Negrini F, de Sire A, Andrenelli E, The International Multiprofessional Steering Committee of Cochrane Rehabilitation REH-COVER action, et al.. Rehabilitation and COVID-19: a rapid living systematic review 2020 by Cochrane Rehabilitation Field. Update as of October 31st, 2020. Eur J Phys Rehabil Med. 2020;56(5).
    1. Siddiq MAB. Pulmonary Rehabilitation in COVID-19 patients: A scoping review of current practice and its application during the pandemic. Turk J Phys Med Rehab. 2020;66(4):480–494.
    1. Kindlon T. Do graded activity therapies cause harm in chronic fatigue syndrome? J Health Psychol. 2017;22(9):1146–1154.
    1. Torjesen I. NICE backtracks on graded exercise therapy and CBT in draft revision to CFS guidance. BMJ. 2020;371:m4356.
    1. Johansson M, Stahlberg M, Runold M, et al. . Long-Haul Post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: the Swedish experience. JACC Case Rep. 2021;3(4):573–580.
    1. Kanjwal K, Jamal S, Kichloo A, et al. . New-onset Postural Orthostatic Tachycardia Syndrome Following Coronavirus Disease 2019 Infection. J Innov Cardiac Rhythm Manage. 2020;11(11):4302–4304.
    1. Miglis MG, Prieto T, Shaik R, et al. . A case report of postural tachycardia syndrome after COVID-19. Clin Auton Res. 2020;30(5):449–451.
    1. Miller A. COVID-19: not just an acute illness. Trends Urology & Men Health. 2020;11(6):17–19.
    1. Perrin R, Riste L, Hann M, et al. . Into the looking glass: Post-viral syndrome post COVID-19. Med Hypotheses. 2020;144:110055.
    1. Afrin LB, Weinstock LB, Molderings GJ.. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327–332.
    1. Kazama I. Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome? Drug Discov Ther. 2020;14(5):259–261.
    1. Gebremeskel S, Schanin J, Coyle KM, et al. . Mast cell and eosinophil activation are associated with COVID-19 and TLR-mediated viral inflammation: implications for an anti-Siglec-8 antibody. Front Immunol. 2021;12:650331.
    1. Zhou Z, Ren L, Zhang L, et al. . Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020;27(6):883–890 e2.
    1. Shibao C, Arzubiaga C, Roberts LJ, et al. . Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45(3):385–390.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa